Survival of stage IV melanoma in Belgium and the Netherlands

K.P.M. Suijkerbuijk; J.B.A.G. Haanen; M.J. Boers-Sonderen; G.A.P. Hospers; C.U. Blank; F.W.P.J. vanden Berkmortel; J.W.B. deGroot; D. Piersma; M.J.B. Aarts; R.S. van Rijn; G. Vreugdenhil; H.M. Westgeest; E. Kapiteijn; A.A.M. van derVeldt; A.J.M. vanden Eertwegh

doi:10.1111/jdv.17668

Survival of stage IV melanoma in Belgium and the Netherlands

K.P.M. Suijkerbuijk^*, J.B.A.G. Haanen, M.J. Boers-Sonderen, G.A.P. Hospers, C.U. Blank, F.W.P.J. vanden Berkmortel, J.W.B. deGroot, D. Piersma, M.J.B. Aarts, R.S. van Rijn, G. Vreugdenhil, H.M. Westgeest, E. Kapiteijn, A.A.M. van derVeldt, A.J.M. vanden Eertwegh

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	E118-E119
Number of pages	2
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	36
Issue number	2
Early online date	30 Sept 2021
DOIs	https://doi.org/10.1111/jdv.17668
Publication status	Published - Feb 2022

Access to Document

10.1111/jdv.17668

Cite this

Suijkerbuijk, K. P. M., Haanen, J. B. A. G., Boers-Sonderen, M. J., Hospers, G. A. P., Blank, C. U., vanden Berkmortel, F. W. P. J., deGroot, J. W. B., Piersma, D., Aarts, M. J. B., van Rijn, R. S., Vreugdenhil, G., Westgeest, H. M., Kapiteijn, E., van derVeldt, A. A. M., & vanden Eertwegh, A. J. M. (2022). Survival of stage IV melanoma in Belgium and the Netherlands. Journal of the European Academy of Dermatology and Venereology, 36(2), E118-E119. https://doi.org/10.1111/jdv.17668

@article{10668542873e43e3b52adce31339b2be,

title = "Survival of stage IV melanoma in Belgium and the Netherlands",

author = "K.P.M. Suijkerbuijk and J.B.A.G. Haanen and M.J. Boers-Sonderen and G.A.P. Hospers and C.U. Blank and {vanden Berkmortel}, F.W.P.J. and J.W.B. deGroot and D. Piersma and M.J.B. Aarts and {van Rijn}, R.S. and G. Vreugdenhil and H.M. Westgeest and E. Kapiteijn and {van derVeldt}, A.A.M. and {vanden Eertwegh}, A.J.M.",

note = "Funding Information: Prof vd Eertwegh has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. Dr Boers‐Sonderen has consultancy/advisory relationships with Pierre Fabre, MSD and Novartis. Dr de Groot has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, Novartis. Prof Hospers consultancy/advisory relationships with Amgen, Bristol Myers Squibb, Roche, MSD, Pfizer, Novartis, Pierre Fabre and has received research grants not related to this paper from Bristol Myers Squibb, Seerave. Dr Kapiteijn has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, and received research grants not related to this paper from Bristol Myers Squibb. Dr Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Abbvie and received honoraria from Novartis, MSD and Roche. All paid to institution. Dr vd Veldt has consultancy relationships with Bristol Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai, Merck. Prof Haanen has advisory relationships with Aimm, Achilles Therapeutics, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb BioNTech,, GSK, Immunocore, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics,, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm and has received research grants not related to this paper from Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics and Novartis. All grants were paid to the institutions. Dr Aarts has advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD‐Merck, Merck‐Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Research grants Merck‐Pfizer. Not related to current work and paid to institute. Dr v Rijn has no disclosures. Dr vd Berkmortel has no disclosures. Dr Vreugdenhil has no disclosures. Prof. Blank reports personal fees from BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures, grants from BMS, Novartis, NanoString, other from Uniti Cars, Forty Seven, Neon Therapeutics, Verastem, other from Immagene B.V. Dr. Piersma reports personal fees from Pierre Fabre, Amgen, BMS. Dr Westgeest reports Travel expenses from Ipsen, Astellas and received honoraria from Roche, Astellas.",

year = "2022",

month = feb,

doi = "10.1111/jdv.17668",

language = "English",

volume = "36",

pages = "E118--E119",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

Suijkerbuijk, KPM, Haanen, JBAG, Boers-Sonderen, MJ, Hospers, GAP, Blank, CU, vanden Berkmortel, FWPJ, deGroot, JWB, Piersma, D, Aarts, MJB, van Rijn, RS, Vreugdenhil, G, Westgeest, HM, Kapiteijn, E, van derVeldt, AAM & vanden Eertwegh, AJM 2022, 'Survival of stage IV melanoma in Belgium and the Netherlands', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 2, pp. E118-E119. https://doi.org/10.1111/jdv.17668

TY - JOUR

T1 - Survival of stage IV melanoma in Belgium and the Netherlands

AU - Suijkerbuijk, K.P.M.

AU - Haanen, J.B.A.G.

AU - Boers-Sonderen, M.J.

AU - Hospers, G.A.P.

AU - Blank, C.U.

AU - vanden Berkmortel, F.W.P.J.

AU - deGroot, J.W.B.

AU - Piersma, D.

AU - Aarts, M.J.B.

AU - van Rijn, R.S.

AU - Vreugdenhil, G.

AU - Westgeest, H.M.

AU - Kapiteijn, E.

AU - van derVeldt, A.A.M.

AU - vanden Eertwegh, A.J.M.

N1 - Funding Information: Prof vd Eertwegh has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. Dr Boers‐Sonderen has consultancy/advisory relationships with Pierre Fabre, MSD and Novartis. Dr de Groot has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, Novartis. Prof Hospers consultancy/advisory relationships with Amgen, Bristol Myers Squibb, Roche, MSD, Pfizer, Novartis, Pierre Fabre and has received research grants not related to this paper from Bristol Myers Squibb, Seerave. Dr Kapiteijn has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, and received research grants not related to this paper from Bristol Myers Squibb. Dr Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Abbvie and received honoraria from Novartis, MSD and Roche. All paid to institution. Dr vd Veldt has consultancy relationships with Bristol Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai, Merck. Prof Haanen has advisory relationships with Aimm, Achilles Therapeutics, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb BioNTech,, GSK, Immunocore, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics,, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm and has received research grants not related to this paper from Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics and Novartis. All grants were paid to the institutions. Dr Aarts has advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD‐Merck, Merck‐Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Research grants Merck‐Pfizer. Not related to current work and paid to institute. Dr v Rijn has no disclosures. Dr vd Berkmortel has no disclosures. Dr Vreugdenhil has no disclosures. Prof. Blank reports personal fees from BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures, grants from BMS, Novartis, NanoString, other from Uniti Cars, Forty Seven, Neon Therapeutics, Verastem, other from Immagene B.V. Dr. Piersma reports personal fees from Pierre Fabre, Amgen, BMS. Dr Westgeest reports Travel expenses from Ipsen, Astellas and received honoraria from Roche, Astellas.

PY - 2022/2

Y1 - 2022/2

U2 - 10.1111/jdv.17668

DO - 10.1111/jdv.17668

M3 - Comment/Letter to the editor

C2 - 34536304

SN - 0926-9959

VL - 36

SP - E118-E119

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 2

ER -